Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 7/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.44 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.36 |
| ▸ | MTOR | P42345 | 1/20 | 0.36 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.34 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.34 |
| ▸ | MERTK | Q12866 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.33 |
| ▸ | AURKA | O14965 | 1/20 | 0.33 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3058838 | 1.00 | NAMPT (0.47) | NAMPTHDAC1CD274CYP2C9MAPKAPK2 | |
| SCHEMBL3048972 | 0.90 | NAMPT (0.55) | NAMPTHDAC1CD274MAPKAPK2PIK3CA | |
| SCHEMBL3053311 | 0.88 | NAMPT (0.48) | NAMPTHDAC1CD274MAPKAPK2PIK3CA | |
| SCHEMBL3055649 | 0.87 | NAMPT (0.41) | NAMPTHDAC1CYP2C9MTORTGFBR1 | |
| SCHEMBL3058841 | 0.86 | NAMPT (0.46) | NAMPTHDAC1CYP2C9MAPKAPK2PIK3CA | |
| SCHEMBL3053090 | 0.80 | NAMPT (0.47) | NAMPTJAK2POLB | |
| SCHEMBL3051338 | 0.80 | NAMPT (0.48) | NAMPTPOLB | |
| SCHEMBL3045731 | 0.80 | NAMPT (0.54) | NAMPTHDAC1MAPKAPK2PIK3CAMTOR | |
| SCHEMBL485950 | 0.80 | NAMPT (0.45) | NAMPTHDAC1CD274JAK2 | |
| SCHEMBL3055634 | 0.79 | NAMPT (0.47) | NAMPTJAK2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100222319-A1 | NICOTINAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-09-02 | — | — | US | claimed |
| US-20100222319-A1 | NICOTINAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222319-A1 | NICOTINAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | NNT, NAMPT, NQO1 | NAMPT 2/4885HDAC1 84/4885CD274 3104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.